UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-to-Severe Psoriasis
Shots:
- The P-III BE SURE study involves assessing bimekizumab vs Humira (adalimumab) for 24wks. is followed until 56wks. in 478 adult patients with chronic PsO for at least 6 mos. before screening & with an affected body surface area of at least 10%- PASI of at least 12 & IGA score equal to or > 3 on a 5point scale
- Results: The study met its 1EPs & 2EPs- @16wks. PASI 90 (86.2% vs 47.2%); IGA 0/1 (85.3 % vs 57.2%); PASI 100 (60.8% vs 23.9%); PASI 100 @24wks. (66.8% vs 29.6%); PASI 90- PASI 100 and IGA 0/1 response rates were maintained through 1year with both q4w & q8w; skin clearance rates increased in patients who switched from adalimumab to bimekizumab @24wks.- with response rates @56wks. comparable to patients treated with bimekizumab throughout the study
- Bimekizumab is an investigational humanized IgG1 mAb that selectively inhibits both IL-17A & IL-17F
Ref: PRNewswire | Image: Pharma Journalist
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com